The Radioligand Therapy (RLT) space is experiencing a period of unprecedented growth and innovation. Driven by major acquisitions, significant venture funding, and compelling clinical data, radiopharmaceuticals are rapidly moving from a niche modality to a mainstream pillar of oncology. Navigating this dynamic ecosystem requires a clear understanding of the key players, from emerging biotech startups to established commercial leaders.
This guide provides a comprehensive overview of 55 companies shaping the future of radiopharmaceuticals, compiled from the ProGen Search 2025 Radiopharma Market Intelligence Report (a much deeper analysis of the entire industry – available upon request).
Note – this information is up to date as of start of Q2 2025, as per public records.
ProGen Search partners with radiopharma innovators like those found on this list to build the leadership teams that drive success. If you are scaling your team or navigating the unique talent challenges in this space, book a confidential consultation with us today.
Alpha Therapy Pioneers
These companies are focused on harnessing the potent power of alpha-emitting isotopes like Actinium-225 and Lead-212 to deliver powerful, targeted blows to cancer cells.
-
- Headquarters: South San Francisco, CA, USA & Vancouver, BC, Canada
-
- Focus: Precision oncology using next-generation targeted alpha and beta radiation therapies developed via its proprietary ROVER™ (Radio Optimized Vector Engineering) platform.
-
- Key Pipeline Asset: ABD-147, a DLL3-targeted ²²⁵Ac therapy for Small Cell Lung Cancer (SCLC), is in Phase 1 trials.
2. Actinium Pharmaceuticals, Inc.
-
- Headquarters: New York, NY, USA
-
- Focus: Developing Antibody Radiation Conjugates (ARCs) using Actinium-225 (²²⁵Ac) for blood cancers and solid tumors.
-
- Key Pipeline Asset: Iomab-B, a CD45-targeted ¹³¹I therapy, has shown positive Phase 3 results for bone marrow transplant conditioning in relapsed/refractory Acute Myeloid Leukemia (AML).
-
- Headquarters: Boston, MA & Research Triangle Park, NC, USA
-
- Focus: Developing novel targeted alpha radiopharmaceuticals (using ²²⁵Ac) based on a miniprotein platform designed for high tumor penetration.
-
- Key Pipeline Asset: AKY-1189 is a first-in-class, Nectin-4 targeted alpha radioconjugate currently in clinical development.
-
- Headquarters: Osaka, Japan
-
- Focus: Designing and developing radiopharmaceuticals using Astatine-211 (²¹¹At), an alpha-emitter produced via cyclotrons.
-
- Key Pipeline Asset: The company’s work is linked to Osaka University’s Phase 1 trial of [²¹¹At]NaAt for thyroid cancer.
-
- Headquarters: Boston, MA, USA & Vancouver, BC, Canada
-
- Focus: Developing bespoke targeted radiopharmaceuticals using an iterative optimization process for binder, linker, chelator, and radioisotope.
-
- Key Pipeline Asset: A Phase 1 trial is underway for an MC1R inhibitor targeting melanoma.
-
- Headquarters: Berlin, Germany
-
- Focus: Developing targeted systemic radiopharmaceuticals for neuroendocrine and other aggressive cancers, targeting SSTR2 and PARP inhibitors.
-
- Key Pipeline Asset: ²²⁵Ac-satoreotide is in a Phase 1/2 trial for SCLC and has received FDA Orphan Drug Designation.
7. ARTBIO Inc.
-
- Headquarters: Cambridge, MA, USA
-
- Focus: Developing Lead-212 (²¹²Pb) alpha radioligand therapies supported by a unique distributed manufacturing ecosystem called AlphaDirect™.
-
- Key Pipeline Asset: AB001, a ²¹²Pb-based therapy for prostate cancer, has commenced first-in-human studies.
8. Atonco
-
- Headquarters: Saint-Herblain (Nantes), France
-
- Focus: Developing alpha-immunotherapies using Astatine-211 (²¹¹At) to eradicate residual cancer cells, particularly non-muscle-invasive bladder cancer (NMIBC).
-
- Key Pipeline Asset: A Phase 2 trial is underway for ²¹¹At-girentuximab, targeting CAIX in NMIBC.
9. Convergent Therapeutics, Inc.
-
- Headquarters: Cambridge, MA, USA
-
- Focus: Developing next-generation alpha-radioantibodies using Actinium-225, with a focus on a PSMA target for prostate cancer.
-
- Key Pipeline Asset: CONV 01-α (²²⁵Ac-rosopatamab tetraxetan) is in a Phase 1/2 trial for mCRPC.
-
- Headquarters: Schlieren (Zurich), Switzerland
-
- Focus: Developing DARPin® (Designed Ankyrin Repeat Protein) therapeutics, including Radio-DARPin Therapy (RDT) using Lead-212.
-
- Key Pipeline Asset: MP0712, a DLL3-targeted ²¹²Pb DARPin, is preparing for first-in-human studies in 2025.
11. Modulation Therapeutics, Inc.
-
- Headquarters: Morgantown, WV, USA
-
- Focus: Developing novel therapeutics including alpha therapies using ²²⁵Ac.
-
- Key Pipeline Asset: MTI-201, a ²²⁵Ac peptide targeting MC1R for metastatic uveal melanoma, has an approved IND for a Phase 1 trial.
12. Orano Med
-
- Headquarters: A subsidiary of Orano Group (France), with operations in the US.
-
- Focus: A vertically integrated company developing Targeted Alpha Therapy (TAT) using Lead-212 (²¹²Pb).
-
- Key Pipeline Asset: AlphaMedix™, a SSTR-targeted ²¹²Pb peptide for neuroendocrine tumors, has received FDA Breakthrough Therapy Designation.
Beta & Other Emitter Innovators
These companies are focused on clinically validated beta emitters like Lutetium-177 and are also exploring other isotopes like Rhenium-186 and Copper-67.
-
- Headquarters: Milan, Italy
-
- Focus: Precision radiotherapy using its YntraDose® platform, which involves local administration of Yttrium-90 (⁹⁰Y) microspheres directly into solid tumors.
-
- Key Pipeline Asset: Phase 1/2 trials are ongoing for liver cancer and pancreatic cancer.
14. Cellectar Biosciences, Inc.
-
- Headquarters: Florham Park, NJ, USA
-
- Focus: Developing proprietary Phospholipid Drug Conjugates™ (PDCs) for targeted delivery of radioisotopes like Iodine-131.
-
- Key Pipeline Asset: Iopofosine I 131 has completed a Phase 2 study for Waldenström’s macroglobulinemia (WM), with a confirmatory study planned for Accelerated Approval.
15. Clarity Pharmaceuticals Ltd.
-
- Headquarters: Sydney, Australia
-
- Focus: Developing copper-based theranostics (TCT) using paired ⁶⁴Cu (diagnostic) and ⁶⁷Cu (therapeutic) isotopes.
-
- Key Pipeline Asset: The SAR-bisPSMA program for prostate cancer is in a Phase 1/2 trial.
16. ITM Isotope Technologies Munich SE
-
- Headquarters: Garching (Munich), Germany
-
- Focus: A vertically integrated company developing and supplying targeted therapeutics and diagnostics, operating the world’s largest ¹⁷⁷Lu facility.
-
- Key Pipeline Asset: ITM-11 (n.c.a. ¹⁷⁷Lu-edotreotide) showed positive results in its Phase 3 COMPETE trial for GEP-NETs, with an NDA submission planned for 2025.
-
- Headquarters: Houston, TX, USA
-
- Focus: Developing targeted radiotherapeutics using Rhenium isotopes (¹⁸⁶Re, ¹⁸⁸Re) within its RNL™ (Rhenium NanoLiposome) platform for CNS cancers.
-
- Key Pipeline Asset: REYOBIQ™ (¹⁸⁶Re obisbemeda) is in ongoing Phase 1/2 trials for glioblastoma (GBM) and leptomeningeal metastases (LM).
-
- Headquarters: New York, NY / Princeton, NJ, USA
-
- Focus: A commercial-stage company prioritizing its novel SADA (Self-Assembly DisAssembly) Pretargeted Radioimmunotherapy (PRIT) platform, which plans to use ¹⁷⁷Lu payloads.
-
- Key Pipeline Asset: A Phase 1 trial is ongoing for its GD2-SADA construct and another is initiating for a CD38-SADA construct.
Platform & Technology Specialists
These companies are defined by their unique, proprietary platforms designed to create best-in-class delivery vehicles for radioisotopes.
-
- Headquarters: Madison, WI, USA
-
- Focus: Developing therapies based on the alkylphosphocholine analog NM600, which can be labeled with various isotopes for PET imaging or therapy.
-
- Key Pipeline Asset: Preclinical programs are underway for ¹⁷⁷Lu-NM600 for breast cancer and ²²⁵Ac-NM600 for prostate cancer.
-
- Headquarters: Cambridge, UK & Cambridge, MA, USA
-
- Focus: Developing novel therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, including Bicycle® Radioconjugates (BRCs).
-
- Key Pipeline Asset: The company has presented human radiopharmaceutical imaging data for its MT1-MMP targeting program.
21. Molecular Targeting Technologies, Inc. (MTTI)
-
- Headquarters: West Chester, PA, USA
-
- Focus: Developing targeted molecules for cancer and infection, featuring its EvaThera™ platform which uses an Evans Blue moiety to extend the half-life of peptide radiopharmaceuticals.
-
- Key Pipeline Asset: EBTATE® (¹⁷⁷Lu-DOTA-EB-TATE) for neuroendocrine tumors is in ongoing clinical studies.
22. Precirix NV
-
- Headquarters: Brussels, Belgium
-
- Focus: Developing precision radiopharmaceuticals based on camelid single-domain antibodies (sdAbs or Nanobodies®).
-
- Key Pipeline Asset: A Phase 1 trial of CAM-H2 (¹³¹I) in metastatic breast cancer has been completed. A Phase 1/2 trial is planned for its FAP-targeted sdAb.
23. Radiomer Therapeutics Inc.
-
- Headquarters: Houston, TX, USA
-
- Focus: Developing targeted radioligand therapies using its proprietary Raptamer™ platform, which are peptide-oligonucleotide hybrids.
-
- Key Pipeline Asset: A Phase 0 imaging trial for its lead Raptamer imaging agent, RPT-⁶⁴Cu, was expected in Q1 2025.
24. Starpharma Holdings Limited
-
- Headquarters: Melbourne, Australia
-
- Focus: Developing dendrimer-based products using its proprietary DEP® (Dendrimer Enhanced Product) platform for drug delivery and radiotheranostics.
-
- Key Pipeline Asset: The company has reported positive preclinical data for its DEP® HER2 radiodiagnostic and radiotherapeutic programs.
25. 3B Pharmaceuticals GmbH (3BP)
-
- Headquarters: Berlin, Germany
-
- Focus: A private biotech developing peptide-targeted radiopharmaceuticals with a business model heavily reliant on partnering its pipeline assets.
-
- Key Pipeline Asset: The company’s discovered assets are in multiple clinical trials with partners, including a FAP-targeted program with Novartis and an NTR1-targeted program with Fusion/AstraZeneca.
Theranostic & Diverse Pipeline Developers
This large group of companies is developing a wide range of assets, often with a specific focus on paired diagnostics and therapeutics, or pursuing multiple targets and platforms simultaneously.
26. Actithera Inc.
-
- Focus: Developing novel small molecule and peptide radiotherapeutics targeting Fibroblast Activation Protein (FAP).
-
- Pipeline: Its lead FAP program uses ⁶⁸Ga for imaging and ¹⁷⁷Lu for therapy and has demonstrated prolonged tumor retention in preclinical studies.
27. Advanced Innovative Partners (AIP)
-
- Focus: Developing theranostic radiopharmaceuticals for a wide range of diseases including oncology, Parkinson’s, and rare pediatric diseases, with a focus on integrins.
-
- Pipeline: Claims to have multiple programs in Phase 1, 2, and 3, including AIP-201 for Parkinson’s Disease (Phase 3).
28. Bivision Pharmaceuticals, Inc.
-
- Focus: A China-based company developing next-generation targeted radionuclide therapies (TRT) using proprietary linker and labeling platforms.
-
- Pipeline: Its lead asset, JH02, is a small molecule ¹⁷⁷Lu-PSMA therapy for mCRPC with INDs approved in both the US and China.
-
- Focus: A UK-based company developing next-generation “radiohybrid” (rh) agents that can be labeled with either diagnostic or therapeutic isotopes.
-
- Pipeline: Its lead therapeutic, ¹⁷⁷Lu-rhPSMA-10.1, is in an active Phase 2 trial for mCRPC.
-
- Focus: A Korean company developing and commercializing radioligand therapies, with a strong focus on PSMA and FAP targets.
-
- Pipeline: Its lead therapeutic, ¹⁷⁷Lu-PSMA-DGUL, is in a pivotal clinical trial for prostate cancer and has received Orphan Drug designation.
-
- Focus: Developing PET imaging agents and biopharma services focused on detecting Granzyme B to assess the efficacy of cancer immunotherapies.
-
- Pipeline: Its lead PET imaging agent, CSB-321, has an approved IND and is ready for Phase 1. A parallel radiotherapeutic program is also in development.
32. Full-Life Technologies Ltd.
-
- Focus: A fully integrated global company based in China developing Radionuclide Drug Conjugates (RDCs) via its UniRDC™ platform.
-
- Pipeline: Its ²²⁵Ac-FL-020 therapy for mCRPC has received FDA Fast Track Designation.
33. GlyTherix Ltd.
-
- Focus: An Australian company developing antibody-based radiopharmaceuticals targeting Glypican-1 (GPC-1) for various solid tumors.
-
- Pipeline: Phase 1b trials for its diagnostic (⁸⁹Zr-Miltuximab®) and therapeutic (¹⁷⁷Lu-Miltuximab®) agents were planned for early 2025.
34. Immunome, Inc.
-
- Focus: A targeted oncology company that is expanding into radiopharmaceuticals discovered via its human memory B cell platform.
-
- Pipeline: Its lead radioligand therapy, IM-3050, targets FAP and was expected to have an IND filed in Q1 2025.
-
- Focus: Developing proprietary therapeutics, with a radiopharma platform targeting uPAR using its MNPR-101 antibody.
-
- Pipeline: A Phase 1 imaging trial for MNPR-101-Zr is ongoing, and a Phase 1a therapy trial for MNPR-101-Lu was initiated in late 2024.
36. Norroy Biosciences Co., Ltd.
-
- Focus: A China-based company developing theranostics for refractory urinary and digestive tract cancers.
-
- Pipeline: The lead therapeutic candidate, ¹⁷⁷Lu-NY108 for mCRPC, has approved INDs in both China and the US.
37. NuView Life Sciences, Inc.
-
- Focus: Developing paired radiopharmaceuticals based on its NV-VPAC1™ peptide, which targets the VPAC1 receptor overexpressed in many cancers.
-
- Pipeline: The company is developing an in vitro diagnostic kit, an in vivo PET imaging agent (⁶⁴Cu-NV-VPAC1), and a therapeutic agent (⁶⁷Cu-NV-VPAC1).
38. Oncoinvent ASA
-
- Focus: A Norwegian company developing Radspherin®, an alpha-particle therapy using Radium-224, for the local treatment of metastatic cancers in body cavities.
-
- Pipeline: A randomized Phase 2 trial of Radspherin® in ovarian cancer is ongoing and has FDA Fast Track Designation.
-
- Focus: A German company developing CXCR4-targeted peptide radiopharmaceuticals (PentixaFor/PentixaTher) for oncology and other diseases.
-
- Pipeline: Its diagnostic, PentixaFor, is in Phase 3 for lymphoma in the EU. Its therapeutic, PentixaTher, is in Phase 1/2 for various blood cancers.
40. PeptiDream Inc.
-
- Focus: A Japanese peptide discovery company with a radiopharma subsidiary (PDRadiopharma) that markets products and develops a pipeline of peptide-RI conjugates (RI-PDCs).
-
- Pipeline: The company has numerous partnered programs, including with Novartis, Curium (for PSMA I&T, currently in Phase 3), and RayzeBio.
41. Perseus Proteomics Inc. (PPMX)
-
- Focus: A Japanese antibody drug discovery company with a radiopharma focus on RI-labeled antibodies (RIT).
-
- Pipeline: Its lead RIT program, PPMX-T002, targets CDH3 and is being repositioned for alpha therapy with ²²⁵Ac.
42. Perspective Therapeutics Inc.
-
- Focus: Pioneering targeted alpha therapies (TAT) using Lead-212 (²¹²Pb) produced via its proprietary VMT-α-GEN generator.
-
- Pipeline: The company has two lead assets in ongoing Phase 1/2a trials: one for neuroendocrine tumors and another for metastatic melanoma.
43. Philogen S.p.A.
-
- Focus: An Italian company developing small molecule radioconjugates targeting ACP3 and FAP for theranostic use.
-
- Pipeline: A Phase 1 trial for its FAP-targeted therapy, ¹⁷⁷Lu-OncoFAP-23, was approved to begin in Q1 2025.
44. Radiopharm Theranostics Ltd.
-
- Focus: An Australian clinical-stage company developing diagnostic and therapeutic agents by licensing diverse technology platforms.
-
- Pipeline: Key assets include RAD 101 (¹⁸F-Pivalate imaging, Phase 2b), RAD 204 (¹⁷⁷Lu-PDL1 mAb, Phase 1), and RAD 301 (⁶⁸Ga-Trivehexin imaging, Phase 1).
45. Radiomedix, Inc.
-
- Focus: A Houston-based company with a hybrid model of developing its own targeted radiotheranostics and providing CDMO services.
-
- Pipeline: The company’s lead internal asset, AlphaMedix™ (²¹²Pb), for neuroendocrine tumors was licensed to Sanofi in September 2024.
-
- Focus: Developing novel small molecule radiotherapeutics targeting G-protein coupled receptors (GPCRs).
-
- Pipeline: Phase 1 trials have been initiated for two diagnostic agents: ⁶⁸Ga-R8760 for Adrenocortical Carcinoma and ⁶⁸Ga-R10602 for HR+ Breast Cancer.
-
- Focus: Developing targeted radiopharmaceuticals using its integrated Trillium™ and Macropa™ platforms.
-
- Pipeline: The company is developing its own FAP-targeted therapeutic while partnering its platforms with major pharma, including Lantheus, Novartis, and Bayer.
48. Starget Pharma
-
- Focus: An Israeli company developing peptide-based Smart Targeted Radioligands (STRs) using a proprietary AI-driven discovery engine.
-
- Pipeline: A Phase 1b trial is planned for its lead candidate, SGT-680.
49. ImaginAb, Inc.
-
- Focus: Post an asset sale to Telix, the company now focuses on its lead imaging agent, CD8 ImmunoPET™ (⁸⁹Zr crefmirlimab berdoxam), as a biomarker in immuno-oncology trials.
-
- Pipeline: CD8 ImmunoPET™ is in Phase 2 trials for oncology and other indications.
Commercial & Late-Stage Leaders
These are established, often publicly traded, companies with significant revenues from approved radiopharmaceutical products and deep, late-stage pipelines.
50. Curium Pharma
-
- Headquarters: Paris, France
-
- Focus: A vertically integrated global leader in nuclear medicine, providing diagnostic (SPECT/PET) and therapeutic agents from a portfolio of over 50 products.
-
- Pipeline: The company has a growing oncology focus, particularly with ¹⁷⁷Lu therapies, and has a partnership with PeptiDream for a PSMA agent in Japan.
-
- Headquarters: North Billerica, MA, USA
-
- Focus: A leading radiopharmaceutical company with a “Find, Fight and Follow®” strategy, covering diagnostics, therapeutics, and AI solutions.
-
- Pipeline: Its blockbuster PSMA PET diagnostic PYLARIFY® drives strong revenue, while its late-stage therapeutic pipeline includes PNT2002 (¹⁷⁷Lu-PSMA-I&T) in the Phase 3 SPLASH study.
52. Sinotau Pharmaceutical Group
-
- Headquarters: Beijing, China
-
- Focus: An integrated Chinese radiopharma company with a strategy that includes in-licensing products for the China market alongside internal development.
-
- Pipeline: The company has launched the Alzheimer’s diagnostic Florbetaben F 18 in China and has a ¹⁷⁷Lu-based therapy for NETs in Phase 2/3.
53. Telix Pharmaceuticals Limited
-
- Headquarters: Melbourne, Australia
-
- Focus: A commercial-stage, vertically integrated biopharma company developing and commercializing a broad pipeline of theranostics.
-
- Pipeline: Generates strong revenue from its approved PSMA imaging agent Illuccix® and has submitted a BLA for its kidney cancer imaging agent, Zircaix. Its therapeutic pipeline includes TLX591 (¹⁷⁷Lu-PSMA Rx) in a Phase 3 trial.
Out-licensing & Partnership Focused
These companies specialize in discovery and early development, with a primary business model of out-licensing their assets to larger partners.
54. Debiopharm International SA
-
- Headquarters: Lausanne, Switzerland
-
- Focus: An independent Swiss biopharma with a model of in-licensing assets, developing them to proof-of-concept, and then out-licensing them for further development.
-
- Pipeline: Its peptide-based CAIX-targeting theranostic program (Debio 0228) was out-licensed to ITM Isotope Technologies in September 2024.
55. 3B Pharmaceuticals GmbH (3BP)
-
- Headquarters: Berlin, Germany
-
- Focus: A private biotech developing peptide-targeted radiopharmaceuticals with a business model heavily reliant on partnering its pipeline assets.
-
- Pipeline: The company’s discovered assets are in multiple clinical trials with partners, including a FAP-targeted program with Novartis and an NTR1-targeted program with Fusion/AstraZeneca.
The radiopharmaceutical landscape is one of the most exciting and complex fields in biotech. Securing the right leadership – executives who can navigate GMP manufacturing, dual regulatory frameworks, and complex supply chains – is the critical factor for success.If you’re building, investing in, or scaling a radiopharma company, ProGen Search can help you find the talent to lead it. Contact us for a confidential discussion about your hiring roadmap.
Click here to book a call today, and click here to see how we help our clients find new talent.
